Health stocks today: Abbott (NYSE: ABT) jumps 11% as insurers split
Abbott Laboratories jumped 10.9%, lifting the XLV healthcare benchmark on Thursday. Managed-care shares moved in both directions.
Abbott tops earnings estimates, raises outlook as second-half sales ramps up
Abbott Laboratories bumped up its 2026 earnings outlook on Thursday after reporting better-than-expected second-quarter results, thanks mostly to cancer tests and heart devices. Shares jumped almost 4% in early trading. The company left its revenue forecast steady, but now has to deliver second-half growth between about 8.6% and 10.5% to hit its target after putting up 4.3% growth in the first half.
Healthcare Stocks: J&J, UnitedHealth, Abbott Face Test on Sector’s 9% Earnings Drop
NEW YORK, July 12, 2026, 4:33 p.m. EDT — Healthcare stocks head into the week with Johnson & Johnson, UnitedHealth and Abbott set to gauge whether the sector’s reported 9% earnings decline is showing up in results.
US Stock Market Today: S&P 500, Nasdaq Hit Record Highs as Wall Street Bets on Ceasefire, Earnings
The S&P 500 and Nasdaq pushed to new intraday records Thursday, with Wall Street staying in rally mode amid optimism that Middle East tensions could cool. As of 11:38 a.m. ET, the S&P 500 had climbed 0.27% to 7,041.34, while the Nasdaq advanced 0.38% to 24,106.40. The Dow inched up, adding 0.06% to reach 48,494.13.
SCHD Draws Fresh Attention After New Dividend and 2026 Reconstitution
The Schwab U.S. Dividend Equity ETF is back in focus, with a new quarterly payout and a March reshuffling of its holdings putting dividend strategies back in the spotlight during uncertain times. SCHD hovered near $30.57 late Monday morning in New York.
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High
Schwab U.S. Dividend Equity ETF, with $83.9 billion in assets, pushed further into health care during its annual portfolio shake-up. Abbott Laboratories and UnitedHealth Group are now among its largest holdings, as cash continues to pour into dividend-focused funds.
Abbott stock price: Insider buy and fresh AFib data put ABT back on watch for Monday
Abbott Laboratories finished Friday up 1.6% at $110.83, logging a second consecutive day of gains, yet still lagging the wider U.S. rally. Roughly 9.9 million shares changed hands—well above its 50-day average. Even so, Abbott’s price stayed about 22% under its 52-week peak of $141.23 set back on March 4 last year, according to MarketWatch data.
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy
Abbott Laboratories edged up 1.6% to finish at $110.83 on Friday, notching a back-to-back advance. The stock lagged behind the S&P 500’s 1.97% jump and the Dow’s 2.47% rally. Abbott is still trading 21.53% under its 52-week peak at $141.23. Volume came in at 9.9 million shares, above the 50-day average of 8.9 million.
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch
Shares of Abbott Laboratories dipped 0.6% to $108.77 Tuesday afternoon after the U.S. Food and Drug Administration issued a warning letter to Abbott Diabetes Care. The letter, dated Jan. 23, criticized the company’s process for verifying the accuracy of its FreeStyle Libre continuous glucose monitors. Specifically, the FDA said Abbott failed to ensure key accuracy specs were passed to third-party manufacturers and released finished devices without conducting accuracy tests at launch. Abbott has 15 business days to respond. Earlier, the stock had fallen as much as 2.9%.
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date
Abbott Laboratories shares were last up 0.1% at $109.43 on Monday after Barclays lowered its 12-month target price to $142 from $169, citing reduced estimates and a lower valuation multiple but keeping an Overweight rating. A price target is an analyst estimate; Overweight signals it expects the stock to outperform its coverage universe.
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations
Abbott Laboratories shares were down about 0.3% at $109.00 in afternoon trade, after Barclays lowered its price target to $142 from $169 while keeping an Overweight rating. The stock traded between $108.94 and $110.97, with about 6.1 million shares changing hands.
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT
Abbott Laboratories shares ended Friday up 3.03%, closing at $109.30. The stock’s recent swings have investors zeroing in on one thing: what Abbott can actually deliver in the upcoming quarter and how fast confidence might return.
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week
Abbott Laboratories shares closed Friday roughly 3% higher, settling at $109.30. During the session, the stock fluctuated between $105.72 and $109.47.
Abbott stock jumps 3% into the weekend as Wall Street resets targets after earnings wobble
Abbott Laboratories shares ended Friday roughly 3% higher, closing at $109.30. The stock had dipped to a session low around $105.72 earlier, with volume picking up noticeably as traders wrapped up the week.
Abbott stock rebounds as Exact Sciences vote nears after broker upgrade
Abbott Laboratories shares climbed roughly 2.6%, closing in on $108.89 Friday afternoon after earlier dipping to $105.72. The stock hit a peak of $109.34 during the session.
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings
Shares of Boston Scientific Corp closed Thursday roughly 1.6% lower at $92.33, having fluctuated between $91.48 and $94.25 during the session.
Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries
Abbott Laboratories shares ticked up 0.3%, reaching $106.34 in Thursday afternoon trading, following a choppy week that held the healthcare giant close to its recent lows.
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next
Abbott Laboratories shares slipped 2.1%, closing at $106.05 Wednesday, despite CEO Robert Ford purchasing roughly $2 million worth of stock via a family trust. The Form 4 filing — a required SEC disclosure for insider trades — reveals Ford acquired 18,800 shares on Jan. 23 at a weighted average price of $107.1259. On that day, the stock fluctuated between $105.28 and $108.58, with about 15.1 million shares changing hands.
Abbott Laboratories stock price slides as Argus cuts target and CEO Ford discloses share buy
Abbott Laboratories shares slipped roughly 2% to $106.12 in afternoon trading Wednesday, hitting a low of $105.90. The drop came after a new price-target downgrade added to the pressure on the medical products company, coming off last week’s earnings reset.
Abbott stock price slips after hours as CEO Ford discloses $2 million share buy
Abbott Laboratories shares slipped 0.5% to $108.27 in late after-hours trading Tuesday, down from a close of $108.82. A recent SEC filing revealed that Chairman and CEO Robert B. Ford purchased 18,800 shares on Jan. 23, paying an average of about $107.13 per share via the Ford Family Trust.